Marshall Fordyce Sells 18,500 Shares of Vera Therapeutics (NASDAQ:VERA) Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce sold 18,500 shares of the business’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $35.12, for a total transaction of $649,720.00. Following the sale, the chief executive officer owned 235,244 shares in the company, valued at $8,261,769.28. This trade represents a 7.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Marshall Fordyce also recently made the following trade(s):

• On Tuesday, July 7th, Marshall Fordyce sold 46,250 shares of Vera Therapeutics stock. The stock was sold at an average price of $42.30, for a total transaction of $1,956,375.00.
• On Tuesday, June 23rd, Marshall Fordyce sold 18,500 shares of Vera Therapeutics stock. The shares were sold at an average price of $37.93, for a total transaction of $701,705.00.

Vera Therapeutics Trading Up 2.6%

Shares of VERA stock opened at $35.89 on Friday. Vera Therapeutics, Inc. has a fifty-two week low of $21.96 and a fifty-two week high of $56.05. The company has a 50 day moving average price of $35.86 and a 200 day moving average price of $37.46. The stock has a market capitalization of $2.59 billion, a P/E ratio of -6.12 and a beta of 0.96. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.92 and a current ratio of 10.92.

Vera Therapeutics (NASDAQ:VERA) last released its earnings results on Monday, August 10th. The company reported ($1.52) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.58) by $0.06. During the same quarter last year, the business earned ($1.20) EPS. Equities research analysts predict that Vera Therapeutics, Inc. will post -6.45 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. Guggenheim increased their price target on Vera Therapeutics from $56.00 to $76.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. The Goldman Sachs Group reissued a “buy” rating and set a $90.00 price objective on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Needham & Company LLC set a $125.00 target price on shares of Vera Therapeutics in a report on Wednesday, July 8th. Wedbush reiterated a “neutral” rating and set a $34.00 price target on shares of Vera Therapeutics in a report on Monday, August 17th. Finally, Bank of America increased their price objective on shares of Vera Therapeutics from $65.00 to $70.00 and gave the company a “buy” rating in a research report on Tuesday, July 7th. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $81.15.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Vera Therapeutics by 7.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,905 shares of the company’s stock worth $753,000 after purchasing an additional 2,210 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Vera Therapeutics by 22.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 98,013 shares of the company’s stock valued at $2,354,000 after purchasing an additional 17,907 shares in the last quarter. Jane Street Group LLC increased its stake in Vera Therapeutics by 297.1% in the first quarter. Jane Street Group LLC now owns 41,578 shares of the company’s stock valued at $999,000 after purchasing an additional 62,678 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in Vera Therapeutics by 550.5% during the second quarter. JPMorgan Chase & Co. now owns 310,547 shares of the company’s stock worth $7,316,000 after purchasing an additional 262,805 shares in the last quarter. Finally, Legal & General Group Plc raised its holdings in Vera Therapeutics by 1.7% during the second quarter. Legal & General Group Plc now owns 50,418 shares of the company’s stock worth $1,188,000 after purchasing an additional 825 shares in the last quarter. Hedge funds and other institutional investors own 99.21% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.